Tuberculosis and Respiratory Diseases最新文献

筛选
英文 中文
Update in Association between Lung Cancer and Air Pollution. 肺癌与空气污染之间关系的最新进展。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-04-01 Epub Date: 2024-12-11 DOI: 10.4046/trd.2024.0092
Jiye Yoo, Yongchan Lee, Youngil Park, Jongin Lee, Joon Young Choi, Heekwan Lee, Jeong Uk Lim
{"title":"Update in Association between Lung Cancer and Air Pollution.","authors":"Jiye Yoo, Yongchan Lee, Youngil Park, Jongin Lee, Joon Young Choi, Heekwan Lee, Jeong Uk Lim","doi":"10.4046/trd.2024.0092","DOIUrl":"10.4046/trd.2024.0092","url":null,"abstract":"<p><p>A significant portion of newly diagnosed lung cancer cases occurs in populations exposed to air pollution. The World Health Organization has identified air pollution as a human carcinogen, prompting many countries to implement monitoring systems for ambient particulate matter (PM). PM is composed of a complex mixture of organic and inorganic particles, both solid and liquid, that are found in the air. Given the carcinogenic properties of PM and the high prevalence of lung cancer among exposed populations, exploring their connection and clinical implications is critical for effectively preventing lung cancer in this group. This review explores the relationship between ambient PM and lung cancer. Epidemiological studies have demonstrated a dose-response relationship between PM exposure and lung cancer risk. PM exposure induces oxidative stress, disrupts the body's redox balance, and causes DNA damage, which is a crucial factor in cancer development. Recent findings on the strong correlation between ambient PM and adenocarcinoma highlight the importance of understanding the specific molecular and pathological mechanisms underlying pollution-related lung cancer. In addition to efforts to control emission sources at the international level, a more individualized approach is essential for preventing PM-related lung cancer.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"228-236"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Severe Asthma Registry (ISAR): 2017-2024 Status and Progress Update. 国际严重哮喘登记(ISAR): 2017-2024状态和进展更新。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-04-01 Epub Date: 2025-02-06 DOI: 10.4046/trd.2024.0198
Désirée Larenas-Linnemann, Chin Kook Rhee, Alan Altraja, John Busby, Trung N Tran, Eileen Wang, Todor A Popov, Patrick D Mitchell, Paul E Pfeffer, Roy Alton Pleasants, Rohit Katial, Mariko Siyue Koh, Arnaud Bourdin, Florence Schleich, Jorge Máspero, Mark Hew, Matthew J Peters, David J Jackson, George C Christoff, Luis Perez-de-Llano, Ivan Cherrez-Ojeda, João A Fonseca, Richard W Costello, Carlos A Torres-Duque, Piotr Kuna, Andrew N Menzies-Gow, Neda Stjepanovic, Peter G Gibson, Paulo Márcio Pitrez, Celine Bergeron, Celeste M Porsbjerg, Camille Taillé, Christian Taube, Nikolaos G Papadopoulos, Andriana I Papaioannou, Sundeep Salvi, Giorgio Walter Canonica, Enrico Heffler, Takashi Iwanaga, Mona S Al-Ahmad, Sverre Lehmann, Riyad Al-Lehebi, Borja G Cosio, Diahn-Warng Perng, Bassam Mahboub, Liam G Heaney, Pujan H Patel, Njira Lugogo, Michael E Wechsler, Lakmini Bulathsinhala, Victoria Carter, Kirsty Fletton, David L Neil, Ghislaine Scelo, David B Price
{"title":"International Severe Asthma Registry (ISAR): 2017-2024 Status and Progress Update.","authors":"Désirée Larenas-Linnemann, Chin Kook Rhee, Alan Altraja, John Busby, Trung N Tran, Eileen Wang, Todor A Popov, Patrick D Mitchell, Paul E Pfeffer, Roy Alton Pleasants, Rohit Katial, Mariko Siyue Koh, Arnaud Bourdin, Florence Schleich, Jorge Máspero, Mark Hew, Matthew J Peters, David J Jackson, George C Christoff, Luis Perez-de-Llano, Ivan Cherrez-Ojeda, João A Fonseca, Richard W Costello, Carlos A Torres-Duque, Piotr Kuna, Andrew N Menzies-Gow, Neda Stjepanovic, Peter G Gibson, Paulo Márcio Pitrez, Celine Bergeron, Celeste M Porsbjerg, Camille Taillé, Christian Taube, Nikolaos G Papadopoulos, Andriana I Papaioannou, Sundeep Salvi, Giorgio Walter Canonica, Enrico Heffler, Takashi Iwanaga, Mona S Al-Ahmad, Sverre Lehmann, Riyad Al-Lehebi, Borja G Cosio, Diahn-Warng Perng, Bassam Mahboub, Liam G Heaney, Pujan H Patel, Njira Lugogo, Michael E Wechsler, Lakmini Bulathsinhala, Victoria Carter, Kirsty Fletton, David L Neil, Ghislaine Scelo, David B Price","doi":"10.4046/trd.2024.0198","DOIUrl":"10.4046/trd.2024.0198","url":null,"abstract":"<p><p>The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"193-215"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Connective Tissue Disease Associated Interstitial Lung Disease. 韩国肺间质性疾病的诊断和治疗指南:结缔组织疾病相关的肺间质性疾病。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-04-01 Epub Date: 2025-01-10 DOI: 10.4046/trd.2024.0148
Ju Hyun Oh, Jae Ha Lee, Sung Jun Chung, Young Seok Lee, Tae-Hyeong Kim, Tae-Jung Kim, Joo Hun Park
{"title":"Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Connective Tissue Disease Associated Interstitial Lung Disease.","authors":"Ju Hyun Oh, Jae Ha Lee, Sung Jun Chung, Young Seok Lee, Tae-Hyeong Kim, Tae-Jung Kim, Joo Hun Park","doi":"10.4046/trd.2024.0148","DOIUrl":"10.4046/trd.2024.0148","url":null,"abstract":"<p><p>Connective tissue disease (CTD), comprising a range of autoimmune disorders, is often accompanied by lung involvement, which can lead to life-threatening complications. The primary types of CTDs that manifest as interstitial lung disease (ILD) include rheumatoid arthritis, systemic sclerosis, Sjögren's syndrome, mixed CTD, idiopathic inflammatory myopathies, and systemic lupus erythematosus. CTD-ILD presents a significant challenge in clinical diagnosis and management due to its heterogeneous nature and variable prognosis. Early diagnosis through clinical, serological, and radiographic assessments is crucial for distinguishing CTD-ILD from idiopathic forms and for implementing appropriate therapeutic strategies. Hence, we have reviewed the multiple clinical manifestations and diagnostic approaches for each type of CTD-ILD, acknowledging the diversity and complexity of the disease. The importance of a multidisciplinary approach in optimizing the management of CTD-ILD is emphasized by recent therapeutic advancements, which include immunosuppressive agents, antifibrotic therapies, and newer biological agents targeting specific pathways involved in the pathogenesis. Therapeutic strategies should be customized according to the type of CTD, the extent of lung involvement, and the presence of extrapulmonary manifestations. Additionally, we aimed to provide clinical guidance, including therapeutic recommendations, for the effective management of CTD-ILD, based on patient, intervention, comparison, outcome (PICO) analysis.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"247-263"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bibliometric Analysis of Nontuberculous Mycobacteria Research in South Korea. 韩国非结核分枝杆菌研究的文献计量分析。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-04-01 Epub Date: 2025-01-14 DOI: 10.4046/trd.2024.0158
Geunin Lee, Young Ae Kang, Youngmok Park
{"title":"Bibliometric Analysis of Nontuberculous Mycobacteria Research in South Korea.","authors":"Geunin Lee, Young Ae Kang, Youngmok Park","doi":"10.4046/trd.2024.0158","DOIUrl":"10.4046/trd.2024.0158","url":null,"abstract":"<p><strong>Background: </strong>Current research on nontuberculous mycobacteria (NTM) is multidisciplinary, necessitating proper organization to obtain comprehensive insight. Therefore, a bibliometric analysis was performed to identify NTM research characteristics in South Korea.</p><p><strong>Methods: </strong>The Web of Science was searched for NTM articles authored by Koreans at Korean institutions until March 2023. We collected data on authors, publication year, article type, study design, research area, citations, research institutes, and funding sources.</p><p><strong>Results: </strong>Of the 28,092 articles on NTM, Koreans authored 868. After excluding 167 unrelated studies, 701 relevant articles were analyzed. The first study was from 1992, with publication rates markedly increasing from 2004 onward. Basic research constituted 41.3% (n=290) of the papers, whereas clinical research represented 44.7% (n=313). Basic research consisted mostly of biochemistry studies (n=73, 10.4%), whereas clinical research primarily involved retrospective studies (n=118, 16.8%). Fifty-four institutions participated in NTM research, with the top five contributing to 71% (n=498) of the publications. The National Research Foundation of Korea was the most significant funding source, supporting 181 studies (32.5% of funded articles). Citation analysis revealed a median citation count of 10 (interquartile range, 3 to 13), with clinical research dominating the top-cited articles and a rise in publications in high-impact journals over time.</p><p><strong>Conclusion: </strong>The quality and quantity of NTM research in South Korea has improved. However, it is concentrated in a few institutions and is largely funded by a few sources. Future research should use more diverse funding sources, be conducted in more institutions, and prioritize prospective study designs to enhance the understanding and treatment of NTM.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"353-360"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Request for Study Design Modification in Examining Nutritional Intake and Muscle Strength in Individuals with Airflow Limitation. 请求修改研究设计,以检查气流受限患者的营养摄入和肌肉力量。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-04-01 Epub Date: 2024-11-25 DOI: 10.4046/trd.2024.0171
Ming-Che Chang, Chii-Lan Lin, Fong-Fong Tsai, Hwei-Mei Tai, Chih-Wei Kuo, Hon-Kwong Ma, Chih-Chung Shiao
{"title":"Request for Study Design Modification in Examining Nutritional Intake and Muscle Strength in Individuals with Airflow Limitation.","authors":"Ming-Che Chang, Chii-Lan Lin, Fong-Fong Tsai, Hwei-Mei Tai, Chih-Wei Kuo, Hon-Kwong Ma, Chih-Chung Shiao","doi":"10.4046/trd.2024.0171","DOIUrl":"10.4046/trd.2024.0171","url":null,"abstract":"","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"408-410"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Anticancer Effects of Histone Deacetylase Inhibitors CG-745 and Suberoylanilide Hydroxamic Acid in Non-small Cell Lung Cancer. HDAC抑制剂CG-745和SAHA对非小肺癌细胞的抗癌作用比较。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-04-01 Epub Date: 2025-02-13 DOI: 10.4046/trd.2024.0090
Hyo Jin Kim, Ui Ri An, Han Jee Yoon, Hyun Lim, Ki Eun Hwang, Young Suk Kim, Hak Ryul Kim
{"title":"Comparison of Anticancer Effects of Histone Deacetylase Inhibitors CG-745 and Suberoylanilide Hydroxamic Acid in Non-small Cell Lung Cancer.","authors":"Hyo Jin Kim, Ui Ri An, Han Jee Yoon, Hyun Lim, Ki Eun Hwang, Young Suk Kim, Hak Ryul Kim","doi":"10.4046/trd.2024.0090","DOIUrl":"10.4046/trd.2024.0090","url":null,"abstract":"<p><strong>Background: </strong>Histone deacetylase (HDAC) inhibition offers potential anticancer effects across diverse cancers due to HDAC&apos;s significant role in cancer development and progression. Consequently, we demonstrated the therapeutic efficacy of the novel HDAC inhibitor, CG-745, in comparison with existing inhibitors such as suberoylanilide hydroxamic acid (SAHA) in non-small cell lung cancer (NSCLC) cells.</p><p><strong>Methods: </strong>CG-745&apos;s effect on apoptosis and reactive oxygen species (ROS)-dependent mitochondrial dysfunction was investigated using annexin V assay, MitoSoX, and Western blot in human A549 and H460 cells. Additionally, HDAC expression was analyzed through real-time polymerase chain reaction. We also evaluated the inhibitory effect of CG-745 on epithelial-mesenchymal transition (EMT) induced by transforming growth factor β1 (TGF-β1) via Western blot, scratch analysis, and matrigel invasion analysis.</p><p><strong>Results: </strong>Compared to SAHA, CG-745 inhibited cell viability and mRNA expression of HDACs such as HDAC1, HDAC2, HDAC3, and HDAC8. It also induced apoptosis, ROS, and mitochondrial dysfunction in a concentration-dependent manner. CG-745 reversed EMT triggered by TGF-β1 in A549 and H460 cells, and curtailed the migration and invasion enhanced by TGF-β1. CG-745 has demonstrably inhibited EMT and induced apoptosis in NSCLC cells.</p><p><strong>Conclusion: </strong>CG-745 may represent a novel therapeutic strategy for NSCLC treatment.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"342-352"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics of Chronic Obstructive Pulmonary Disease according to Smoking Status. 根据吸烟状况确定慢性阻塞性肺病的临床特征。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI: 10.4046/trd.2024.0060
Joo Hun Park
{"title":"Clinical Characteristics of Chronic Obstructive Pulmonary Disease according to Smoking Status.","authors":"Joo Hun Park","doi":"10.4046/trd.2024.0060","DOIUrl":"10.4046/trd.2024.0060","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) can be caused by various factors, including lung infections, asthma, air pollution, childhood growth disorders, and genetic factors, though smoking is the predominant risk factor. The main pathological mechanisms in COPD involve small airway disease, emphysema, mucus hypersecretion, and vascular disorders. COPD in non-smokers is characterized by a normal 1-second forced expiratory volume decline, equal sex distribution, younger age of onset, fewer comorbidities, milder airflow obstruction, preserved diffusing capacity of the lungs for carbon monoxide, and radiological features such as more air-trapping and less severe emphysema compared to COPD in smokers. Nevertheless, non-smokers with COPD still experience a high prevalence of acute exacerbations, nearly equal to that of smokers with COPD. Moreover, COPD itself is an independent risk factor for developing lung cancer, regardless of smoking status. Given that COPD coexists with numerous comorbidities, effectively managing these comorbidities is crucial, requiring multifaceted efforts for comprehensive treatment.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"14-25"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Korean Guidelines for the Management and Antibiotic Therapy in Adult Patients with Hospital-Acquired Pneumonia. 韩国医院获得性肺炎成人患者管理和抗生素治疗指南》。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-10-11 DOI: 10.4046/trd.2024.0135
Hayoung Choi, Kyung Hoon Min, Young Seok Lee, Youjin Chang, Bo Young Lee, Jee Youn Oh, Ae-Rin Baek, Jongmin Lee, Kyeongman Jeon
{"title":"Korean Guidelines for the Management and Antibiotic Therapy in Adult Patients with Hospital-Acquired Pneumonia.","authors":"Hayoung Choi, Kyung Hoon Min, Young Seok Lee, Youjin Chang, Bo Young Lee, Jee Youn Oh, Ae-Rin Baek, Jongmin Lee, Kyeongman Jeon","doi":"10.4046/trd.2024.0135","DOIUrl":"10.4046/trd.2024.0135","url":null,"abstract":"<p><p>Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are correlated with high morbidity and mortality rates. Guidelines that consider local epidemiologic data are fundamental for identifying optimal treatment strategies. However, Korea has no HAP/VAP guidelines. This study was conducted by a committee of nine experts from the Korean Academy of Tuberculosis and Respiratory Diseases Respiratory Infection Study Group using the results of Korean HAP/VAP epidemiologic studies. Eleven key questions for HAP/VAP diagnosis and treatment were addressed. The Convergence of Opinion on Suggestions and Evidence (CORE) process was used to derive suggestions, and evidence levels and recommendation grades were in accordance with the Grading of Recommendations Assessment Development and Evaluation (GRADE) methodology. Suggestions were made for the 11 key questions pertinent to diagnosis, biomarkers, antibiotics, and treatment strategies for adult patients with HAP/VAP. Using the CORE process and GRADE methodology, the committee generated a series of recommendations for HAP/VAP diagnosis and treatment in the Korean context.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"69-89"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Miliary Tuberculosis Associated with Klebsiella pneumonia: Managing the Double Whammy of Antimicrobial Resistance. 伴有克雷伯氏菌肺炎的睫状体结核病:抗菌药耐药性的双重打击。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI: 10.4046/trd.2024.0105
Priyavardhan Mishra, Mohit Kondisetti, Anant Patil, Nikhil Sarangdhar, Vijaykumar Gupta
{"title":"Miliary Tuberculosis Associated with Klebsiella pneumonia: Managing the Double Whammy of Antimicrobial Resistance.","authors":"Priyavardhan Mishra, Mohit Kondisetti, Anant Patil, Nikhil Sarangdhar, Vijaykumar Gupta","doi":"10.4046/trd.2024.0105","DOIUrl":"10.4046/trd.2024.0105","url":null,"abstract":"","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"190-192"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary Tuberculosis. 对药物敏感的肺结核进行培养转换后,大剂量利福平治疗 3 个月。
IF 2.5
Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-09-27 DOI: 10.4046/trd.2024.0099
Nakwon Kwak, Joong-Yub Kim, Hyung-Jun Kim, Byoung-Soo Kwon, Jae Ho Lee, Jeongha Mok, Yong-Soo Kwon, Young Ae Kang, Youngmok Park, Ji Yeon Lee, Doosoo Jeon, Jung-Kyu Lee, Jeong Seong Yang, Jake Whang, Kyung Jong Kim, Young Ran Kim, Minkyoung Cheon, Jiwon Park, Seokyung Hahn, Jae-Joon Yim
{"title":"High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary Tuberculosis.","authors":"Nakwon Kwak, Joong-Yub Kim, Hyung-Jun Kim, Byoung-Soo Kwon, Jae Ho Lee, Jeongha Mok, Yong-Soo Kwon, Young Ae Kang, Youngmok Park, Ji Yeon Lee, Doosoo Jeon, Jung-Kyu Lee, Jeong Seong Yang, Jake Whang, Kyung Jong Kim, Young Ran Kim, Minkyoung Cheon, Jiwon Park, Seokyung Hahn, Jae-Joon Yim","doi":"10.4046/trd.2024.0099","DOIUrl":"10.4046/trd.2024.0099","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen.</p><p><strong>Methods: </strong>This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at &lt;6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156).</p><p><strong>Results: </strong>Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups.</p><p><strong>Conclusion: </strong>The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"170-180"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信